Juvenescence Acquires Ro5 to Integrate AI and Machine Learning in Drug Discovery

Juvenescence has completed the acquisition of Ro5, a move aimed at strengthening its artificial intelligence and machine learning capabilities in drug discovery and development. The acquisition is expected to bolster Juvenescence’s research efforts by integrating advanced AI-driven tools into its operations.

Ro5 specializes in applying AI and machine learning technologies to pharmaceutical research, focusing on streamlining drug discovery processes. By incorporating Ro5’s expertise, Juvenescence plans to enhance its ability to identify potential therapeutic compounds more efficiently. This strategic acquisition aligns with Juvenescence’s broader goal of leveraging technology to accelerate innovation within the pharmaceutical sector.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 6, 2025

Author

Mark Chiang